RESEARCH ARTICLE

Comparative Epidemiology of Human Infections with Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome Coronavirus among Healthcare Personnel

Shelan Liu1*, Ta-Chien Chan2*, Yu-Tseng Chu3,4, Joseph Tsung-Shu Wu3,5, Xingyi Geng6, Na Zhao7, Wei Cheng1, Enfu Chen1, Chwan-Chuen King3*

1 Department of Infectious Diseases, Zhejiang Provincial Centre for Disease Control and Prevention, Hangzhou, Zhejiang Province, China, 2 Center for Geographic Information Science, Research Center for Humanities and Social Science, Academia Sinica, Taipei, Taiwan, 3 Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan, 4 Institute of Statistical Science, Academia Sinica, Taipei, Taiwan, 5 Luke International, Malawi Office and Mzuzu University, Mzuzu City, Malawi, 6 Emergency Offices, Jinan Centre for Disease Control and Prevention, Jinan, Shandong Province, China, 7 National Research Center for Wildlife Born Diseases, Key Lab of Animal Ecology and Conservation Biology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China

☯ These authors contributed equally to this work.
* liushelan@126.com (SLL); chwanchuen@gmail.com (CCK)

Abstract

The largest nosocomial outbreak of Middle East respiratory syndrome (MERS) occurred in South Korea in 2015. Health Care Personnel (HCP) are at high risk of acquiring MERS-Coronavirus (MERS-CoV) infections, similar to the severe acute respiratory syndrome (SARS)-Coronavirus (SARS-CoV) infections first identified in 2003. This study described the similarities and differences in epidemiological and clinical characteristics of 183 confirmed global MERS cases and 98 SARS cases in Taiwan associated with HCP. The epidemiological findings showed that the mean age of MERS-HCP and total MERS cases were 40 (24~74) and 49 (2~90) years, respectively, much older than those in SARS (SARS-HCP: 35 (21~68) years, p=0.006; total SARS: 42 (0~94) years, p=0.0002). The case fatality rates (CFR) was much lower in MERS-HCP [7.03% (9/128)] or SARS-HCP [12.24% (12/98)] than the MERS-non-HCP [36.96% (34/92), p<0.001] or SARS-non-HCP [24.50% (61/249), p<0.001], however, no difference was found between MERS-HCP and SARS-HCP [p=0.181]. In terms of clinical period, the days from onset to death [13 (4~17) vs 14.5 (0~52), p=0.045] and to discharge [11 (5~24) vs 24 (0~74), p=0.010] and be hospitalized days [9.5 (3~22) vs 22 (0~69), p=0.040] were much shorter in MERS-HCP than SARS-HCP. Similarly, days from onset to confirmation were shorter in MERS-HCP than MERS-non-HCP [6 (1~14) vs 10 (1~21), p=0.044]. In conclusion, the severity of MERS-HCP and SARS-HCP was lower than that of MERS-non-HCP and SARS-non-HCP due to younger age and early confirmation in HCP groups. However, no statistical difference was found in
MERS-HCP and SARS-HCP. Thus, prevention of nosocomial infections involving both novel Coronavirus is crucially important to protect HCP.

Introduction

Ten years after the outbreaks of Severe Acute Respiratory Syndrome (SARS) occurred in 29 countries, another novel coronavirus named Middle East Respiratory Syndrome coronavirus (MERS-CoV) was first found in the Middle East, in 2012 [1, 2]. The novel coronaviruses responsible for both SARS and MERS infections are zoonotic viruses. Civet cats and bats were identified as the sources of SARS-CoV infections in humans, whereas camels and bats were associated with human MERS-CoV infections [3–5]. Both viruses spread to an intermediate mammalian host from which humans are infected. Although human-to-human transmission occurred, this was mainly within households and medical care facilities, where healthcare personnel (HCP) were affected the most. However, super spreading events were reported in the SARS and MERS outbreak [6, 7].

Previous studies also indicated that HCP were a major high-risk population for infections with SARS-CoV and MERS-CoV [8, 9], but the information was very fragmented. Here, based on a series of HCP laboratory-confirmed MERS and SARS infections obtained from the World Health Organization and Taiwan, respectively, we compared the epidemiological and clinical characteristics, and particular similarities as well as differences between the two coronavirus infections to measure the risks related to fatal outcomes in both HCP and total cases. These data will be of benefit for effective prevention and control for any future nosocomial outbreaks of novel Coronavirus, and will therefore promote occupational health.

Materials and Methods

Sources of study populations

All the laboratory-confirmed MERS cases were obtained from various publicly available sources from April 1 of 2012 to July 7 of 2015, including the published literature and data reported to the World Health Organization (http://www.who.int/csr/don/archive/disease/coronavirus_infections/en/) (S1 Table). All laboratory-confirmed SARS cases were reported to the WHO from Taiwan during November 1 of 2002 to December 31, 2003 (http://www.who.int/csr/sars/country/table2004_04_21/en/), after the final decision by the SARS Advisory Committee members in Taiwan (S2 Table).

Case definitions

According to the WHO guideline, a laboratory-confirmed case with MERS-CoV was defined as either detection of viral nucleic acid or confirmation by serology [10]. Based on the WHO guideline, the case definitions for SARS cases were confirmed by several different laboratory tests, including confirmation of the RT-PCR results from two different laboratories or two different specimens collected from the same person, and/or serological tests by ELISA.

Epidemiologic investigations and laboratory tests

Once cases were suspected to be clinical SARS cases, preliminary investigation was conducted using a standardized questionnaire about demographic characteristics and exposure history, clinical features, and laboratory results. Respiratory samples obtained from any reported
suspected SARS cases were sent to the Center for Disease Control in Taiwan (Taiwan-CDC) for confirmation by RT-PCR or serology. The details of all the laboratory methods (molecular RT-PCR or serological tests) to confirm SARS-CoV were as previously described [11].

Statistical analysis
Regional incidence rates are shown on the map using the bio-geographical information system software ArcGIS Map10.2 (http://resources.arcgis.com/en/home/). We used the ggplot function from the R package “ggplot2” to draw the boxplots of age distribution between MERS and SARS cases.

Quantitative measurements are presented as the mean and range of the observed values, and qualitative measurements are presented as relative and absolute frequencies. Categorical and continuous characteristics were analyzed with a chi-squared test and t test, respectively. All statistical analyses were conducted using SAS 9.2 (SAS Institute, Cary, NC, USA). Any p values given are two-sided and subject to a local significance level of 0.05.

Results
Epidemiological comparison

Geographical distribution. As of 7 July 2015, 1368 laboratory-confirmed human MERS--CoV cases had been reported to the WHO, 487 of whom died (35.6%). All of these MERS cases were distributed in 26 countries, particularly predominant in the Arabian Peninsula and South Korea. However, global MERS-HCP cases occurred in 6 countries; see Table 1 and Fig 1. MER-HCP accounted for 13.37% (183/1368) of overall MERS cases in the world.

By contrast, as of 31 December 2003, 8096 laboratory-confirmed global human SARS-CoV cases had been reported to the WHO, 774 of whom died (9.6%). These SARS cases were distributed in 29 countries, particularly predominant in Asian areas. The percent of the SARS-HCP in total cases was higher than the percent of the MERS-HCP [21.07% (1706/8096) vs 13.37% (183/1368), p<0.001]. The CFR in overall MERS was statistically significantly higher than that of overall SARS [35.6% (487/1368) vs 9.6% (774/8096), p<0.001]. (Table 1 and Fig 2).

Demographical and occupational exposure. The mean age in worldwide total 174 MERS cases was 49 years (range: 2~90 years), of which 143 MERS-HCP cases were aged 40 years (range: 24~74 years), significantly younger than in 31 MERS-non-HCP cases [47.5 years (range: 2~90 years), p = 0.035]. Similarly, the mean age in 347 total Taiwan SARS cases was 42 years (range: 0~94), of which the mean age in 98 SARS-HCP cases was 35 years (range: 21~68 years), also much younger than that of SARS-non-HCP [45 years (range: 0~94 years), p = 0.044]. Noticeably, the mean ages of MERS-HCP and total MERS cases were significantly older than those for SARS-HCP (p = 0.006) and total SARS cases in Taiwan (p = 0.0002). (Fig 3A and 3B and Table 1). We stratified the age groups between the MERS-HCP and SARS-HCP cases; the results show that there are no signature differences in the mean age of the 20~, 30~, 40~, 50~, 60~–70 groups between the two groups.

In terms of sex distribution, among MERS cases whose gender information was available, 65% of 1359 total MERS cases were male, of which 54.46% of 101 MERS-HCP and 69.55% of 1258 MERS-non-HCP [p = 0.002] were male respectively. However, in Taiwan females were dominant in the 98 SARS-HCP cases (82.65%, 81/98) and 249 SARS-non-HCP cases (55.0%, 137/249) [p = 0.027], while males accounted for 46.93% (3778/8050) of total global SARS cases. (Fig 3A and 3B and Table 1). We stratified the gender groups between the MERS-HCP and SARS-HCP cases, with the results showing significant differences in the gender distribution of the 20~, 30~, 40~, 50~, 60~–70 groups between the two groups.
Regarding the working departments of HCP, 58.82% (10/17) of MERS-HCP cases worked in an intensive care unit (ICU), while 17.65% (3/17), 11.76% (2/17), and 11.76% (2/17) worked in Emergency rooms (ER), internal medicine and other departments in hospitals, respectively. Among the 57 of 98 SARS-HCP cases with their information of working departments available, ER (31.58%, 18/57), wards of internal medicine (26.31%, 15/57), and ICU (10.53%, 6/57) and other wards (31.58%, 18/57) were the four major working sites (Table 1). Our statistics for department will be heavily biased because of the missing department information in the HCP infections with MERS and SARS-CoV.

Among total 169 hospital-acquired MERS cases, patients accounted for 46.2%, family members or visitors 34.9%, and HCP (19.0%). Among the 227 laboratory-confirmed SARS cases from hospital infections, HCP accounted the highest (43.2%), followed by patients (28.6%).

Table 1. Epidemiologic comparison of the laboratory-confirmed human infections with MERS-CoV and SARS-CoV* in healthcare personnel (HCP) and total cases as of July 7, 2015.

| Epidemiologic Characteristics | MERS-CoV (+) | SARS-CoV (+) | Comparisons |
|-------------------------------|--------------|--------------|-------------|
|                              | HCP (n = 183) | Total (n = 1368) | p1 | HCP (n = 98)* | Total (n = 8096) | p2 | p3 | p4 |
| Outbreak Area                |              |              |     |              |              |     |     |     |
| No. of countries/areas       | 6            | 26           | NA  | 9             | 29           | NA  | NA  | NA  |
| Most affected Countries      | Saudi Arabia | Saudi Arabia | NA  | China         | China        | NA  | NA  | NA  |
| Epidemic Curve               |              |              |     |              |              |     |     |     |
| Starting month               | April of 2012| April of 2012| NA  | January of 2003| November of 2002| NA  | NA  | NA  |
| Peaking month                | Spring       | Spring and summer | NA | NA  | Spring and winter | NA  | NA  | NA  |
| Months of epidemic period    | >39          | >39          | NA  | 8             | 8            | NA  | NA  | NA  |
| Clusters                     |              |              |     |              |              |     |     |     |
| Super-spreader               | Yes          | Yes          | NA  | Yes           | Yes          | NA  | NA  | NA  |
| Cluster size                 | NA           | 2.3 (1–26)   | NA  | 8 (0–125)     | NA           | NA  | NA  | NA  |
| Outbreak areas               | Hospitals (Hosp) | Hosp, Households (HH) | NA | Hospitals | Hosp, HH, Communities | NA  | NA  | NA  |
| Animal Sources               | No           | Bat and camel | No | NA           | Civet cat and bat | NA  | NA  | NA  |
| Human Cases                  |              |              |     |              |              |     |     |     |
| Percent of HCP cases         | NA           | 13.37% (183/1368) | NA | NA | 21.07% (1706/8096) | NA  | 0.000 | NA  |
| Mean age (yr)                | 40 (24–74)   | 49 (2–90)    | 0.035 | 35 (21–68)* | 42 (0–94)  | 0.044 | 0.006 | 0.0002 |
| Male/total%                  | 54.46% (55/ 101) | 65% (883/1359) | 0.002 | 17.35% (17/98) | 46.93% (3778/8050) | 0.027 | <0.001 | <0.001 |
| Overall CFR                  | NA           | 35.6% (487/1368) | NA | NA | 9.6% (774/8096) | NA  | <0.001 | NA  |
| Working place for HCP        |              |              |     |              |              |     |     |     |
| Emergency rooms              | 17.65% (3/17) | NA          | NA  | 31.58% (18/57) | NA          | NA  | 0.943 | NA  |
| Intensive care units         | 58.82% (10/17) | NA          | NA  | 10.53% (6/57)   | NA          | NA  | <0.001 | NA  |
| Internal medicine wards      | 11.76% (2/17) | NA          | NA  | 26.31% (15/57) | NA          | NA  | 0.704 | NA  |
| Others                       | 11.76% (2/17) | NA          | NA  | 31.58% (18/57) | NA          | NA  | 0.507 | NA  |
| Unknown                      | 166          | NA          | NA  | 41            | NA          | NA  | NA  | NA  |

Denotations: p1: comparison of HCP and non-HCP cases infected with MERS-CoV; p2: comparison of HCP and non-HCP cases infected with SARS-CoV; p3: comparison of HCP infected with MERS-CoV and SARS-CoV; p4: comparison of total MERS-CoV and total SARS-CoV cases. CFR: Case Fatality Rate; NA: No available data

*SARS-CoV Data were obtained from Taiwan.

doi:10.1371/journal.pone.0149988.t001
family members or visitors (19.8%), foreign caregivers (4.4%), and others (4.0%). Nurses were the major populations in both groups (Fig 4A and 4B).

Clinical comparison

Clinical spectrum. The percentages of asymptomatic cases [36.72% (47/128) vs 17.39% (16/92), *p* = 0.001] and mild cases [43.75% (56/128) vs 18.48% (17/92), *p* < 0.001] in HCP were much higher than those in non-HCP. However, the percentage of severe MERS cases in HCP was significantly lower than that in non-HCP [12.5% (16/128) vs 27.17% (25/92), *p* = 0.006]. Similarly, CFR of MERS-HCP was statistically lower than that in MERS-non-HCP [7.0% (9/128) vs 36.96% (34/92), *p* < 0.001] Table 2. By contrast, severe SARS cases were more common in HCP than in non-HCP [86.76% (86/98) vs 75.50% (188/249), *p* = 0.012]. Nonetheless, CFR of SARS in HCP was significantly lower than that in non-HCP [12.24% (12/98) vs. 24.50% (61/249), *p* = 0.012, Table 2]. In general, MERS-HCP were predominantly associated with mild cases whereas SARS-HCP were more likely to develop severe cases. On the other hand, MERS-non-HCP cases had higher CFR than SARS-non-HCP cases [36.96% (34/92) vs 24.50% (61/249), *p* = 0.023, Table 2.

Clinical manifestations. Detailed investigations on clinical manifestations of these two infections in HCP and non-HCP demonstrated that cough was the most frequent symptom in MERS-HCP [63.41% (81/128)], whereas fever was the most common symptom in MERS-non-HCP [97.83% (90/92)]. Additionally, both diarrhea and shortness of breath (SOB) were higher in the MERS-non-HCP compared to the MERS-HCP [26.00% (24/92) vs 2.44% (3/128), *p* < 0.001; 73.91% (68/92) vs 48.78% (62/128), *p* < 0.001, respectively] (Table 2).

Time periods for clinical progress. Three time periods useful for public health surveillance were evaluated (Table 2). In MERS groups, the incubation period (the days from exposure to the clinical presentations) showed no differences between MERS-HCP and MERS-non-HCP [7 (3~11) vs 5 (2.0~15), *p* = 0.150] or between SARS-HCP and SARS-non-HCP cases [6 (1~15) vs 5 (4~6), *p* = 0.250]. The days from onset to being discharged and to death between the two groups also revealed similar results. By contrast, MERS-HCP cases had significantly shorter days from onset to laboratory-confirmation than MERS-non-HCP [6 (1~14) vs 10 (1~21), *p* = 0.044].

In SARS groups, among the three measures, only the days from onset to being discharged showed a difference, with significantly shorter days for SARS-HCP than SARS-non-HCP [19 (2~92) vs 24 (0~74), *p* = 0.002]. Table 2

Among the HCP with SARS and MERS infections, MERS-HCP had significantly longer days from onset to admission than SARS-HCP [5 (0~11) vs 3 (0~14), *p* = 0.010] but a shorter period from onset to being discharged [11 (5~24) vs 24 (0~74), *p* = 0.010]) and to death [13 (4~17) vs 14.5 (0~52), *p* = 0.045] and be hospitalized days [9.5 (3~22) vs 22 (0~69), *p* = 0.040] in MERS-HCP than those in SARS-HCP. Table 2

To minimize the case fatality rate in MERS-HCP and SARS-HCP, we analyzed the epidemiology about the deaths related to HCP infections. 10 fatal MERS-HCP cases from Saudi Arabia, UAE and Jordan, as well as 13 fatal SARS-HCP cases in Taiwan were included (Table 3). The mean age of fatal MERS-HCP cases was 50 (26~67), 70% of them were male, and 40% (4/10) had comorbidities. Similarly, the mean age of the fatal SARS-HCP cases was 49 (28~68),
64.29% of whom were female. 69.23% (9/13) of SARS-HCP cases had accompanying co-morbidities. We found that fatality was most often found in age 50~ groups with co-mortality in both the MERS-HCP and SARS-HCP groups respectively. Most of the fatal SARS-HCP were hired care workers (30.77% (; 4/13), or cleaners or nurses (15.38% (; 2/13). Importantly, the mean age in fatal HCP with the two infections was much older than in survivors of HCP with these infections.

Discussion

MERS-CoV and SARS-CoV infections are caused by the β group of the Coronaviruses (The genomic size of coronaviruses ranges from approximately 26 to 32 kilobases, the largest for an RNA virus), but the two Coronaviruses have different sources of infection and evolution, as shown by phylogenetic studies [2, 12]. One unique common epidemiological characteristic of these two diseases is that the spread of both MERS-CoV and SARS-CoV infection has been largely driven by hospital-associated human-to-human transmission where HCP are affected the most. In addition, these two emerging infections displayed four major differences. First, the geographical distributions for the two infections were different, in that MERS cases occurred mostly in the Middle East areas and South Korea, but a significantly higher number of SARS cases happened in Asia, predominantly in Chinese-concentrated countries and areas, including China. The differing patterns of cases between MERS and SARS may represent varying ecological situations, animal-human contact behavior, surveillance, control efforts, and cross-country spread, etc. [7]. A recent imported MERS case from Korea to Guangdong, China resulted in zero cases in China, further supporting the public health significance of surveillance and contact tracing for emerging infectious diseases. As the spread of MERS has continued, additional countries and areas are anticipated to have future outbreaks due to unexpected new imported cases [13]. Secondly, the two diseases vary in the transmissibility and effectiveness of containment. SARS-CoV cases spread rapidly through person-to-person transmission, aided by super spreaders, and finally reached 8096 total cases and affected 29 countries worldwide in an 8-month period [14]. However, the MERS-CoV cases spread at a slower speed, resulting in less of an emergency than SARS, with a total of at least 1382 cases (as of 11 August 2015), and attacked 26 countries worldwide in a period of over 39 months, without successful containment [15]. However, the South Korean outbreak in hospital involved MERS coronaviruses, with early super-spreading events (29 cases) generating a disproportionately large number of secondary infections, and the transmission potential diminishing greatly in subsequent generations [16]. Aron J. et al. reported 48 health care worker contacts with one death with MERS-CoV, and showed no evidence of MERS-CoV infection, which suggested the transmission was limited, without sustained transmission [12]. Thirdly, global MERS cases had a CFR of 35.6%, much higher than the 9.6% in global SARS cases [17]. This high CFR was probably because many mild and even asymptomatic infections have not been identified, due to insufficient public health resources in the Middle East [18]. The actual CFR for MERS is most likely lower than the currently documented rate. However, the CFR varied for different areas, countries and ages. The CFR was 21% among overall MERS cases sourced from health settings[7]. CFR among patients aged 60 years or older under treatment was estimated at 48.2%, while the CFR among other cases was estimated to lie below 15%. The risk of MERS death was
significantly associated with older age as well as treatment for underlying diseases, etc. [17].

Fourthly, for the MERS cases, 72% (118/163) were found in Saudi Arabia, where the mean age showed its predominance in older males, in contrast to SARS cases in the Taiwan. A gender difference was found in the different age subgroups among two groups. The differences between MERS-HCP and SARS-HCP did not contribute to the age differences between the HCP populations in Saudi Arabia and Taiwan, because the HCP distribution was similar in the two countries. The reasons are not fully understood, but have been attributed to cultural practices in which older men may be more likely to come in contact with camels and other MERS-CoV-positive animals, and male HCP may be more common in the healthcare settings in the Middle East [19].

HCP are the population at highest risk of getting the infection and transmitting the two respiratory CoV due to occupational exposure, and thus are affected mostly in nosocomial outbreaks. The outbreak of SARS in 2003 tragically highlighted a high CFR in HCP [5]. HCP with exposure to MERS-CoV also were found as a personal and family health risks and social stigmatization. Further epidemiological analyses found that younger nurses were the most affected for both diseases compared to total cases. In contrast, MERS–HCP cases were different from SARS–HCP cases, as shown by: (1) a lower percentage of total MERS cases from this study (13.37% vs 21.07%) [supported by the lower seroprevalence of HCP–MERS–CoV [12]]; (2) younger age and more male nurses (probably due to either occupational exposure or a cultural relationship [20]; (3) HCP acquiring the MERS–CoV mostly in ICU (compared to ER for most of the SARS–CoV cases) consistent with other reports [21]. Park BJ, et al. also reported that HCP exposure occurred most frequently in the emergency department (69%) and among nurses (47%) [22]. In other words, HCP with high-risk occupational exposure and working in high-risk areas of medical institutions should be well-educated, alerted, and tested once they demonstrate respiratory-related symptoms/signs, as in Toronto’s experience [23].

The clinical course of MERS generally follows a pattern typical of SARS infections. Our research estimated the incubation periods were 5~7 days in MERS–HCP and SARS–HCP groups, as documented from other reports [24]. Differently, the days from onset to confirmation in MERS–HCP were much shorter than for the total MERS cases. This is attributed to the fact that most HCP had close contact with the primary case and under medical observation. Importantly, the clinical period (from onset to outcome) was much shorter in MERS–HCP than in SARS–HCP. This shows that MERS infections were much more severe, due to higher respiratory tract viral loads, than SARS infections [25]. In addition, this difference was related not only to detection capability, and earliness of medical seeking behavior, but also to medical care handling.

Coronavirus infections range from asymptomatic infection to severe pneumonia and even death. However, there are several important differences between both infections [17]. Firstly, the incidence of asymptomatic and mild infection remains 0.1% for the general population, and there are higher rates for HCP with SARS-CoV (0.22%, n = 453) in Beijing, China [26], far lower than that of MERS infections overall and in HCP respectively. As most MERS–HCP infections were identified in secondary cases, mainly as mild disease or asymptomatic infection [8], those MERS–HCP remained a potential infection source of MERS–CoV. Thus, there is an urgent need for developing a rapid, sensitive, and specific diagnostic test to confirm MERS–CoV infection [27]. Secondly, 70% (7/10) of fatal MERS–HCP were identified in male workers,
Figure 4a.

Figure 4b.
while 61.5% (8/13) of fatal SARS-HCP were in female workers. However, the deadly cases were most often found in those in their 50s age groups with underlying diseases in both the MERS-HCP and SARS-HCP groups respectively. This sex distribution was attributed to gender occupational exposure, sanitation behaviors and gender-specific comorbidities. As for similarities, CFR for both HCP infections were much lower than that of overall infections. This might mean that MERS-HCP and SARS-HCP were due to early confirmation, as well as due to the younger age with fewer accompanying comorbidities and professional guidance in HCP groups. Another common point was that the fatal MERS-HCP and SARS-HCP cases were both

Table 2. Clinical comparisons of the laboratory-confirmed human infections with MERS-CoV and SARS-CoV between healthcare personnel (HCP) and non-HCP.

| Clinical Characteristics | MERS-CoV (+) | SARS-CoV (+) | Comparison |
|--------------------------|-------------|-------------|------------|
|                         | HCP (n = 128) | Non-HCP (n = 92) | p1 | HCP (n = 98) | Non-HCP (n = 249) | p2 | p3 | p4 |
| Clinical Severity        |             |             |          |             |             |          |      |      |
| Asymptomatic             | 36.72% (47/128) | 17.39% (16/92) | <0.0001 | 0.00% (0/98) | 0.00% (0/249) | 0.012 | <0.0001 | <0.0001 |
| Mild                     | 43.75% (56/128) | 18.48% (17/92) | <0.0001 | 0.00% (0/98) | 0.00% (0/249) | 0.012 | <0.0001 | <0.0001 |
| Severe                   | 12.50% (16/128) | 27.17% (25/92) | <0.0001 | 86.76% (86/98) | 75.50% (188/249) | 0.012 | <0.0001 | <0.0001 |
| Fatal                    | 7.03% (9/128) | 36.96% (34/92) | <0.0001 | 12.24% (12/98) | 24.50% (61/249) | 0.012 | <0.0001 | <0.0001 |
| Clinical Symptoms        |             |             |          |             |             |          |      |      |
| Fever (>38°C)            | 58.54% (75/128) | 97.83% (90/92) | <0.001 | 95.92% (94/98) | 83.94% (209/249) | 0.003 | <0.0001 | <0.0001 |
| Cough                    | 63.41% (81/128) | 83.70% (77/92) | <0.001 | 33.67% (33/98) | 38.55% (96/249) | 0.397 | <0.0001 | <0.0001 |
| Chills or rigors          | 55% (70/128) | 84.78% (78/92) | <0.001 | 7.14% (7/98) | 2.01% (5/249) | 0.018 | <0.0001 | <0.0001 |
| Sore throat              | 17.07% (22/128) | 14.00% (13/92) | 0.541 | 3.06% (3/98) | 3.21% (8/249) | 0.942 | <0.0001 | <0.0001 |
| Runny nose               | 9.76% (12/128) | 0.00% (0/92) | 0.006 | 1.02% (1/98) | 1.20% (3/249) | 0.884 | 0.007 | 0.686 |
| Haemoptysis              | 0.00% (0/128) | 17.00% (16/92) | <0.001 | 0.00% (0/98) | 0.00% (0/249) | NA | NA | NA |
| Shortness of breath      | 48.78% (62/128) | 73.91% (68/92) | <0.001 | 1.02% (1/98) | 8.43% (21/249) | 0.010 | <0.001 | <0.001 |
| Headache                 | 0.00% (0/128) | 9.76% (9/92) | <0.001 | 2.04% (2/98) | 4.02% (10/249) | 0.364 | 0.365 | 0.365 |
| Myalgia                  | 14.63% (19/128) | 32.61% (30/92) | 0.001 | 12.24% (12/98) | 5.62% (14/249) | 0.035 | 0.365 | 0.365 |
| Malaise                  | 0.00% (0/128) | 38.00% (35/92) | <0.001 | 1.02% (1/98) | 1.20% (3/249) | 0.884 | 0.365 | 0.365 |
| Nausea                   | 0.00% (0/128) | 21.00% (19/92) | <0.001 | 1.02% (1/98) | 0.00% (0/249) | 0.628 | 0.884 | 0.884 |
| Vomiting                 | 0.00% (0/128) | 21.00% (19/92) | <0.001 | 2.04% (2/98) | 0.80% (2/249) | 0.331 | 0.365 | 0.365 |
| Diarrhea                 | 2.44% (3/128) | 26.00% (24/92) | <0.001 | 13.27% (13/98) | 12.05% (30/249) | 0.757 | 0.004 | 0.002 |
| Rhinorrhea               | 4.88% (6/128) | 5.43% (5/92) | 0.082 | 0.00% (0/98) | 0.00% (0/249) | NA | 0.079 | 0.002 |
| Disease Progression (Days) |             |             |          |             |             |          |      |      |
| Incubation period        | 7 (3–11) | 5 (2.0–15) | 0.150 | 6 (1–15) | 5 (4–6) | 0.250 | 0.890 | 0.640 |
| From onset to admission  | 5 (0–11) | 5 (1–14) | 0.480 | 2 (0–14) | 3 (0–42) | 0.261 | 0.010 | 0.470 |
| From onset to confirmation | 6 (1–14) | 10 (1–21) | 0.044 | 2 (0–20) | 3 (0–42) | 0.416 | 0.250 | 0.770 |
| From onset to death      | 13 (4–17) | 12 (1–52) | 0.930 | 14.5 (0–52) | 12 (0–83) | 0.277 | 0.045 | 0.200 |
| From onset to be discharged | 11 (5–24) | 12 (3–30) | 0.690 | 24 (0–74) | 19 (2–92) | 0.002 | 0.010 | 0.010 |

Denotations: p1: comparison of HCP and Non-HCP cases infected with MERS-CoV; p2: comparison of HCP and Non-HCP cases infected with SARS-CoV; p3: comparison of HCP infected with MERS-CoV and SARS-CoV; p4 value represents comparison of Non-HCP infected with MERS-CoV and SARS-CoV. NA: No available data

*SARS-CoV Data were obtained from Taiwan.

doi:10.1371/journal.pone.0149988.t002
Table 3. Clinical and epidemiological characteristics of fatal infections with MERS-CoV vs SARS-CoV in healthcare personnel (HCP).

| Groups          | Countries       | Case type | Age | Gender | Occupation       | Working place | Comorbidity | Outcome | Death Dates | Data source                                                                 |
|-----------------|-----------------|-----------|-----|--------|------------------|---------------|-------------|---------|-------------|----------------------------------------------------------------------------|
| HCP-MERS        | Saudi Arabia    | Confirmed | 41  | F      | HCP              | Unknown       | No          | Deceased | Unknown     | http://www.moh.gov.sa/en/CCC/pressreleases/pages/mediastatement-2013-09-05-001.aspx |
| HCP-MERS        | Saudi Arabia    | Confirmed | 56  | Unknown| HCP              | Unknown       | No          | Deceased | Unknown     | http://www.moh.gov.sa/en/CoronaNew/P...09-07-001.aspx                     |
| HCP-MERS        | Saudi Arabia    | Confirmed | 40  | F      | HCP              | Unknown       | Yes         | Deceased | Unknown     | http://www.moh.gov.sa/en/CCC/PressRe...28-001.aspx                       |
| HCP-MERS        | Saudi Arabia    | Confirmed | 54  | M      | HCP              | Unknown       | Yes         | Deceased | 1/14/2014    | http://www.peninsulatimes.org/2014/0...gladeshi-mers/                    |
| HCP-MERS        | Saudi Arabia    | Confirmed | 26  | M      | Nurse            | ER            | No          | Deceased | 4/5/2014     | http://www.aleqt.com/2014/03/28/article_836865.html                     |
| HCP-MERS        | UAE             | Confirmed | 45  | M      | HCP              | Unknown       | No          | Deceased | 4/10/2014    | http://www.who.int/csr/don/2014_04_14_mers/en/                           |
| HCP-MERS        | Jordan          | Confirmed | 56  | M      | HCP              | Unknown       | Yes         | Deceased | 5/6/2014     | http://www.assabeel.net/important/it...D9%86%86A7                        |
| HCP-MERS        | Saudi Arabia    | Probable  | 67  | M      | Doctor (Cardiologist) | Unknown       | Yes         | Deceased | 9/5/2013     | xhttp://www.alsharq.net.sa/2013/06/16/869245                              |
| HCP-MERS        | Saudi Arabia    | Confirmed | 60  | M      | Dermatologist    | Unknown       | No          | Deceased | 5/12/2014    | http://www.saudigazette.com.sa/index.cfm?method=home.regcon&contentid=20140514205096 |
| HCP-MERS        | Saudi Arabia    | Confirmed | 54  | M      | Home care Doctor | Private hospital | No          | Deceased | 5/12/2014    | http://www.saudigazette.com.sa/index.cfm?method=home.regcon&contentid=20140514205096 |
| HCP-SARS        | Taiwan          | Confirmed | 52  | F      | HCW              | Unknown       | Yes         | Deceased | 4/19/2004    | Provided by Taiwan University                                             |
| HCP-SARS        | Taiwan          | Confirmed | 42  | M      | Laundry staff    | Laundry room  | Yes         | Deceased | 4/29/2003    | Provided by Taiwan University                                             |
| HCP-SARS        | Taiwan          | Confirmed | 37  | F      | Administration  | Internal ward | No          | Deceased | 5/28/2003    | Provided by Taiwan University                                             |
| HCP-SARS        | Taiwan          | Confirmed | 47  | F      | Nurse            | Unknown       | No          | Deceased | 5/1/2003     | Provided by Taiwan University                                             |
| HCP-SARS        | Taiwan          | Confirmed | 28  | M      | Doctor           | Internal ward | Yes         | Deceased | 5/15/2003    | Provided by Taiwan University                                             |
| HCP-SARS        | Taiwan          | Confirmed | 41  | F      | Microbiologist   | Testing Lab   | Yes         | Deceased | 6/12/2003    | Provided by Taiwan University                                             |
| HCP-SARS        | Taiwan          | Confirmed | 57  | M      | Care giver       | Internal ward | Yes         | Deceased | 4/29/2003    | Provided by Taiwan University                                             |
| HCP-SARS        | Taiwan          | Confirmed | 58  | M      | Care giver       | Internal ward | No          | Deceased | 5/4/2003     | Provided by Taiwan University                                             |

(Continued)
associated with older age with comorbidities (e.g., diabetes, hematological diseases, smoking, etc.), as recorded in other reports [28].

The experience from controlling SARS in Asia was that nosocomial outbreak was associated with a lack of awareness of and preparedness for emerging infections. So, to prevent disease transmission to HCP, early and rapid detection of patients suspected of being infected with MERS SARS diseases would be beneficial to reduce the HCP and patient infections [13]. The second group of risks were overcrowding, medical operations generating virus-containing aerosols, and poorly ventilated environments. Another risk was substandard infection control practices. Therefore, future effort should include more comprehensive ways to control MERS-HCP infections. Firstly, public health effort needs to emphasize establishing systems for early recognition and reporting of HCP cases through a computer-based syndrome surveillance system [29]. These vigilant virologic and epidemiologic surveillance for MERS and SARS viruses should be conducted in HCP in nationwide in winter and spring of every year, which will be valuable to decrease the incidence, severity and transmission of two viruses in HCP working in health settings. Secondly, environmental control should be implemented through better engineering design, ventilation and disinfection in hospitals, regular monitoring and check-up and management policies [30]. Thirdly, rigorous training and practice of the standard operating infection-control procedures, including isolation of suspected or confirmed MERS-CoV cases, putting on and taking off personal protective equipment (PPE) and evaluations thereafter, are necessary.

Ethical Considerations

The MERS data were obtained from publicly available data sources. Since SARS was a legally required notifiable disease in Taiwan in 2003, the data of SARS cases were centralized as a data bank for group data analysis only. All these data were provided and analyzed in an anonymous format, without access to personally identifying information.

Supporting Information

S1 Table. Summary of MERS-HCP cases with onset of illness from April 1 of 2012 to July 7 of 2015.
(XLSX)
S2 Table. Summary of SARS-HCP cases with onset of illness from November 1 of 2002 to December 31, 2003.

(XLSX)

Acknowledgments

Financial support. This study was supported by the Taiwan Science Foundation (NSF Grant #92-2751-B-002-020-Y). We thank the reporting countries with the confirmed MERS case. We appreciated their providing assistance with field investigation, administration and data collection and sending the data to WHO.

Potential conflicts of interest. All authors report no conflicts of interest relevant to this article.

Author Contributions

Conceived and designed the experiments: SLL CCK. Performed the experiments: SLL TCC YTC JTSW. Analyzed the data: TCC YTC JTSW. Contributed reagents/materials/analysis tools: XYG NZ WC EFC. Wrote the paper: SLL.

References

1. Zumla A, Perlman S, McNabb SJ, Shaikh A, Heymann DL, McCloskey B, et al. Middle East respiratory syndrome in the shadow of Ebola. The Lancet Respiratory medicine. 2015; 3(2):100–2. doi: 10.1016/S2213-2600(14)70316-9 PMID: 25592990.
2. de Groot RJ, Baker SC, Baric RS, Brown CS, Drosten C, Enjuanes L, et al. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol. 2013; 87(14):7790–2. doi: 10.1128/JVI.01244-13 PMID: 23678167; PubMed Central PMCID: PMC3700179.
3. Raj VS, Farag EA, Reusken CB, Lamers MM, Pas SD, Voermans J, et al. Isolation of MERS coronavirus from a dromedary camel, Qatar, 2014. Emerging infectious diseases. 2014; 20(8):1339–42. doi: 10.3201/eid2008.140663 PMID: 25075761; PubMed Central PMCID: PMC4111206.
4. Drosten C, Kellam P, Memish ZA. Evidence for camel-to-human transmission of MERS coronavirus. The New England journal of medicine. 2014; 371(14):1359–60. doi: 10.1056/NEJMct1409847 PMID: 25271615.
5. Memish ZA, Mishra N, Olival KJ, Fagbo SF, Kapoor V, Epstein JH, et al. Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerging infectious diseases. 2013; 19(11):1819–23. doi: 10.3201/eid1911.131172 PMID: 24206838; PubMed Central PMCID: PMC3837665.
6. Braden CR, Dowell SF, Jernigan DB, Hughes JM. Progress in global surveillance and response capacity 10 years after severe acute respiratory syndrome. Emerging infectious diseases. 2013; 19(6):864–9. doi: 10.3201/eid1906.130192 PMID: 23731871; PubMed Central PMCID: PMC3713843.
7. Cowling BJ, Park M, Fang VJ, Wu P, Leung GM, Wu JT. Preliminary epidemiological assessment of MERS-CoV outbreak in South Korea, May to June 2015. Euro surveillance: bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin. 2015; 20(25):7–13. PMID: 26132767; PubMed Central PMCID: PMC4535930.
8. Ip M, Chan PK, Lee N, Wu A, Ng TK, Chan L, et al. Seroprevalence of antibody to severe acute respiratory syndrome (SARS)-associated coronavirus among health care workers in SARS and non-SARS medical wards. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2004; 38(12):e116–8. doi: 10.1086/421019 PMID: 15227633.
9. Zumla A, Hui DS. Infection control and MERS-CoV in health-care workers. Lancet. 2014; 383(9932):1869–71. doi: 10.1016/S0140-6736(14)60852-7 PMID: 24857701.
10. WHO. Laboratory Testing for Middle East Respiratory Syndrome Coronavirus Interim guidance (revised) 2015 [cited 2015 June, 2015]. Available from: http://apps.who.int/iris/bitstream/10665/176982/1/WHO_MERS_LAB_15.1_eng.pdf?ua=1.
11. Wu HS, Hsieh YC, Su IJ, Lin TH, Chiu SC, Hsu YF, et al. Early detection of antibodies against various structural proteins of the SARS-associated coronavirus in SARS patients. Journal of biomedical science. 2004; 11(1):117–26. doi: 10.1186/1423-0127-11-1 PMID: 14730215.
12. Hail AJ, Tokars JI, Badreddine SA, Saad ZB, Furukawa E, Al Masri M, et al. Health care worker contact with MERS patient, Saudi Arabia. Emerging infectious diseases. 2014; 20(12):2148–51. doi: 10.3201/eid2012.141211 PMID: 25418612; PubMed Central PMCID: PMC4257796.
13. Suwantarat N, Apisarnthanarak A. Risks to healthcare workers with emerging diseases: lessons from MERS-CoV, Ebola, SARS, and avian flu. Current opinion in infectious diseases. 2015; 28(4):349–61. doi: 10.1097/QCO.0000000000000183 PMID: 26098498.

14. Shen Z, Ning F, Zhou W, He X, Lin C, Chin DP, et al. Superspreading SARS events, Beijing, 2003. Emerging infectious diseases. 2004; 10(2):256–60. doi: 10.3201/eid1002.030732 PMID: 15030693; PubMed Central PMCID: PMC3322930.

15. WHO. Infection prevention and control during health care for probable or confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection [cited 2015 June 4th]. Available from: http://www.who.int/emergencies/mers-cov/mers-cov-republic-of-korea-and-china-risk-assessment-19-june-2015.pdf?ua=1.

16. Chowell G, Abdurizak F, Lee S, Lee J, Jung E, Nishiura H, et al. Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study. BMC medicine. 2015; 13:210. doi: 10.1186/s12916-015-0450-0 PMID: 26336062; PubMed Central PMCID: PMC4558759.

17. Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet. 2015. doi: 10.1016/S0140-6736(15)60454-8 PMID: 26049252.

18. Drosten C, Meyer B, Muller MA, Corman VM, Al-Masri M, Hossain R, et al. Transmission of MERS and SARS in the healthcare setting: a comparative study. BMC medicine. 2015; 13:210. doi: 10.1186/s12916-015-0450-0 PMID: 26336062; PubMed Central PMCID: PMC4558759.

19. Mizumoto K, Endo A, Chowell G, Miyamatsu Y, Saitoh M, Nishiura H. Real-time characterization of risks of death associated with the Middle East respiratory syndrome (MERS) in the Republic of Korea, 2015. BMC medicine. 2015; 13:228. doi: 10.1186/s12916-015-0468-3 PMID: 26420593; PubMed Central PMCID: PMC4588253.

20. Gossner C, Danielson N, Gervelmeyer A, Berthe F, Faye B, Kaasik Aaslav K, et al. Human-Dromedary Camel Interactions and the Risk of Acquiring Zoonotic Middle East Respiratory Syndrome Coronavirus Infection. Zoonoses and public health. 2014. doi: 10.1111/zph.12171 PMID: 25545147.

21. Memish ZA, Al-Tawfiq JA, Makhdoom HQ, Assiri A, Alhakeem RF, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. The Lancet Infectious diseases. 2013; 13(9):752–61. doi: 10.1016/S1473-3099(13)70204-4 PMID: 23891402.

22. Memish ZA, Al-Tawfiq JA, Makhdoom HQ, Assiri A, Alhakeem RF, Albarrak A, et al. Respiratory tract samples, viral load, and genome fraction yield in patients with Middle East respiratory syndrome. The Journal of infectious diseases. 2014; 210(10):1590–4. doi: 10.1093/infdis/jiu292 PMID: 24837403.

23. Leung GM, Lim WW, Ho LM, Lam TH, Ghani AC, Donnelly CA, et al. Seroprevalence of IgG antibodies to SARS-coronavirus in asymptomatic or subclinical population groups. Epidemiology and infection. 2006; 134(2):211–21. doi: 10.1017/S0950268805004826 PMID: 16490123; PubMed Central PMCID: PMC2870380.

24. Memish ZA, Zumla AI, Assiri A. Middle East respiratory syndrome in health care workers. The New England journal of medicine. 2013; 369(9):884–6. doi: 10.1056/NEJMmc1308698 PMID: 239293992.

25. Parry J. WHO warns that death rate from SARS could reach 10%. Bmj. 2003; 326(7397):999. doi: 10.1136/bmj.326.7397.999/a PMID: 12742900; PubMed Central PMCID: PMC1125964.

26. Wu TS, Shih FY, Yen MY, Wu JS, Lu SW, Chang KC, et al. Establishing a nationwide emergency department-based syndromic surveillance system for better public health responses in Taiwan. BMC public health. 2008; 8:18. doi: 10.1186/1471-2458-8-18 PMID: 18201388; PubMed Central PMCID: PMC2249581.

27. Gomersall CD, Joynt GM, Ho OM, Ip M, Yap F, Derrick JL, et al. Transmission of SARS to healthcare workers. The experience of a Hong Kong ICU. Intensive care medicine. 2006; 32(4):564–9. doi: 10.1007/s00134-006-0081-1 PMID: 16505989.